Core Viewpoint - The governance structure of Jinbo Bio (832982.BJ) has undergone significant adjustments following the announcement of a 2 billion yuan fundraising plan involving Zhong Shanshan's company, marking a strategic collaboration between the two entities [1][4]. Group 1: Management Changes - On September 8, the company announced that founder and actual controller Yang Xia has taken over as General Manager, fully responsible for the company's operational management [2]. - The previous General Manager, Jin Xuekun, will continue to oversee the growth sectors, including medical aesthetics, gynecology, and scalp care, with the personnel structure remaining unchanged to ensure strategic continuity and market stability [2][3]. - Yang Xia, born in 1974, has been deeply involved in the company's development since 2008 and currently holds 58.89% of the company's shares [3]. Group 2: Financial Performance - For the first half of 2025, the company achieved a revenue of 859 million yuan, representing a year-on-year growth of 42.43%, while the net profit attributable to shareholders reached 392 million yuan, an increase of 26.65% [3]. - Sales expenses surged to 181 million yuan, a 67.77% increase compared to the same period last year, primarily due to rising salaries for sales personnel, increased stock incentive amortization, and heightened brand promotion investments [3]. Group 3: Strategic Collaboration - The recent management changes include the appointment of Chen Bin, a representative of Zhong Shanshan's affiliated party, to the new board of directors [4]. - Jinbo Bio plans to issue shares to Zhong Shanshan's Yanshengtang, raising a total of 2 billion yuan through a private placement of up to 7.1757 million shares [4]. - Following the completion of the transactions, Zhong Shanshan will hold a total of 10.58% of Jinbo Bio's shares, becoming the second-largest shareholder, while Yang Xia's stake will decrease to 50.73% [4].
锦波生物：杨霞重掌公司运营，“钟睒睒系”获新任董事提名